Luminopia, Inc. Announces Oversubscribed Seed Extension Financing Round

Nov 11, 2022•over 2 years ago

Round Type

seed

CambridgeBiotechnology

Investors

Sony Innovation FundShang Bay Capital

Description

Luminopia, Inc., a prescription digital therapeutics company pioneering a new class of treatments for neuro-visual disorders, today announced an oversubscribed $5.7M seed extension financing round. ShangBay Capital led the round, with participation from Sony Innovation Fund, The Vertical Group, and SSI Strategy, as well as support from existing investors. With the closing of the round, William Dai, Founding Managing Partner of ShangBay Capital, will be joining Luminopia’s Board of Directors.

Company Information

Company

LUMINOPIA

Location

625 MASSACHUSETTS AVENUE

Cambridge, Maryland, United States

About

Luminopia is pioneering a new class of treatments for significant neuro-visual disorders. Luminopia is committed to creating digital therapeutics that are both rigorously evaluated for FDA approval and genuinely engaging for patients. As an Innovation Partner of Boston Children’s Hospital, the company is developing its lead product, Luminopia One, to treat amblyopia, the leading cause of vision loss among children. For more information, visit luminopia.com.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns